Skip to main content
Lunai Bioworks Inc. logo

Lunai Bioworks Inc. — Investor Relations & Filings

Ticker · RENB ISIN · US29350E1047 US Professional, scientific and technical activities
Open in API
Filings indexed 580 across all filing types
Latest filing 2021-12-22 Director's Dealing
Country US United States of America
Listing US RENB

About Lunai Bioworks Inc.

https://www.lunaibio.com

Lunai Bioworks Inc. is a pre-clinical stage biotechnology company that utilizes artificial intelligence for drug discovery and biodefense. The company focuses on pioneering safe and responsible generative biology to develop new therapies. By harnessing phenomics and AI, it aims to decode disease signals and translate them into treatments. Its proprietary Transformer Platform is designed to accelerate drug discovery processes. Lunai Bioworks develops medicines, diagnostics, and biodefense products, with a pipeline that includes programs for neurodegenerative conditions like Alzheimer's disease.

Recent filings

Filing Released Lang Actions
Director's Dealing 2021
Director's Dealing
2021-12-22 English
Director's Dealing 2021
Director's Dealing
2021-12-21 English
Director's Dealing 2021
Director's Dealing
2021-12-21 English
FORM S-8
Regulatory Filings Classification · 95% confidence The document is a Form S-8 registration statement filed with the U.S. Securities and Exchange Commission. It relates to the registration of securities under the Securities Act of 1933, specifically for shares reserved under equity incentive plans. The document includes details about the registration fee, incorporation by reference of prior filings (such as 10-K and 10-Q), and indemnification provisions for directors and officers. Form S-8 is a registration statement used for securities issued under employee benefit plans and is not a financial report, earnings release, or management discussion. It is a regulatory filing related to securities registration and compliance. Therefore, the appropriate classification is Regulatory Filings (RNS). The document length (15,000 characters) and content confirm it is not a brief announcement or a report publication announcement but a substantive regulatory filing.
2021-12-13 English
FORM 8-K
Investor Presentation Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated December 1, 2021, for Enochian BioSciences Inc. It specifically mentions that the filing includes a corporate presentation made available at the World Vaccine & Immunotherapy Congress, attached as Exhibit 99.1. The text states that the presentation is incorporated by reference and is not deemed filed for certain regulatory purposes. The document is short (3664 characters) and primarily serves to announce the availability of the corporate presentation rather than containing the full presentation or detailed financial data itself. According to the classification rules, such a document announcing or attaching a presentation is best classified as an Investor Presentation (IP). The presence of the corporate presentation as an exhibit and the nature of the disclosure align with the Investor Presentation category rather than a full report or regulatory filing. Therefore, the appropriate classification is Investor Presentation (IP) with high confidence.
2021-12-01 English
Director's Dealing 2021
Director's Dealing
2021-11-23 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.